Kristian Reich - Feb 20, 2024 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich
Stock symbol
MLTX
Transactions as of
Feb 20, 2024
Transactions value $
-$1,208,418
Form type
4
Date filed
2/22/2024, 06:32 PM
Previous filing
Feb 16, 2024
Next filing
Feb 29, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$575K -10K -0.33% $57.45 2.99M Feb 20, 2024 See footnote. F1, F2, F3
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$574K -10K -9.09% $57.43 100K Feb 20, 2024 Direct F1, F4
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$28.2K -509 -0.02% $55.31 2.99M Feb 21, 2024 See footnote. F1, F3, F5
transaction MLTX Class A ordinary shares, par value $0.0001 per share Sale -$31.5K -569 -0.57% $55.30 99.5K Feb 21, 2024 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
F2 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.06 to $59.09. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3 Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
F4 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.14 to $59.09. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.225 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F6 The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.15 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.